key: cord-0919925-8qvhu1pk
authors: Tomé, Inês; Francisco, Vitor; Fernandes, Hugo; Ferreira, Lino
title: High-throughput screening of nanoparticles in drug delivery
date: 2021-08-26
journal: APL Bioeng
DOI: 10.1063/5.0057204
sha: 1bdec8848f2e5e4f397f4a2a23971a7cec6c5a22
doc_id: 919925
cord_uid: 8qvhu1pk

The use of pharmacologically active compounds to manage and treat diseases is of utmost relevance in clinical practice. It is well recognized that spatial-temporal control over the delivery of these biomolecules will greatly impact their pharmacokinetic profile and ultimately their therapeutic effect. Nanoparticles (NPs) prepared from different materials have been tested successfully in the clinic for the delivery of several biomolecules including non-coding RNAs (siRNA and miRNA) and mRNAs. Indeed, the recent success of mRNA vaccines is in part due to progress in the delivery systems (NP based) that have been developed for many years. In most cases, the identification of the best formulation was done by testing a small number of novel formulations or by modification of pre-existing ones. Unfortunately, this is a low throughput and time-consuming process that hinders the identification of formulations with the highest potential. Alternatively, high-throughput combinatorial design of NP libraries may allow the rapid identification of formulations with the required release and cell/tissue targeting profile for a given application. Combinatorial approaches offer several advantages over conventional methods since they allow the incorporation of multiple components with varied chemical properties into materials, such as polymers or lipid-like materials, that will subsequently form NPs by self-assembly or chemical conjugation processes. The current review highlights the impact of high-throughput in the development of more efficient drug delivery systems with enhanced targeting and release kinetics. It also describes the current challenges in this research area as well as future directions.

The use of nanotechnologies for the prevention, diagnosis, and treatment of diseases in medicine can have a major impact on human health. The design and development of nanoparticles (NPs) for drug delivery is an area of nanomedicine that has received great attention. NPs are used to (i) increase therapeutic efficacy, (ii) decrease the therapeutically effective dose, and/or (iii) reduce the risk of systemic side effects; and these can be achieved by improving the solubility, by controlling the passive and/or active targeting, or by endogenously and/or exogenously triggering release of the payload. 1, 2 Despite their therapeutic advantages and the promising results obtained in preclinical studies, the number of NP-based products used in the clinic is still limited. In 2016, there were 25 Food and Drug Administration (FDA) or European Medicines Agency (EMA) approved nanomedicines, and more than 45 NP formulations that were under evaluation in clinical trials. 3 Some recent approvals include two lipid formulations for patients with acute myeloid leukemia, 4 treatment of polyneuropathy caused by transthyretin amyloidosis, 5 and an inorganic formulation for oncology applications. 6 There are also two authorized vaccines based in nanoparticle formulations (Pfizer-BioNTech 7 and Moderna 8 ) containing mRNA to prevent COVID-19 disease. Moreover, preclinical studies and clinical trials with NPs have shown promising results in cancer treatment 9 and combined delivery of therapeutic agents, such as small molecules, genes, and biorelevant molecules. 10 To increase the impact of nanomedicine in the clinic, several experimental challenges need to be addressed. 11 From a biological perspective, the fate of intact and disassembled NPs in vivo, particularly their interaction with blood components and intercellular compartments, is critical to understand their mechanisms of action. 12 From a nanomaterial perspective, parameters such as batch-to-batch reproducibility and scale-up production under GMP-compliance need to be addressed. In addition, the identification of nanomaterials able to target specific tissues and cells, and deliver intracellularly different types of biomolecules, are required. In most studies, the identification of the best formulation was done by testing a small number of formulations or by modification of pre-existent ones. Unfortunately, this is a low throughput and time-consuming process that likely prevents the identification of formulations with the highest potential and/or with a tailor-made composition for a given application. For example, the recent development of a siRNA delivery formulation for the treatment of hereditary transthyretin amyloidosis took more than 10 years of development. 13 More than 300 ionizable lipids were synthesized to find the best formulation for the delivery of the siRNA in the liver of mice. 14 High-throughput combinatorial design and screening of NP libraries may be an alternative to allow the rapid screening of multiple formulations to identify the ones with a specific release profile and/or with cell/tissue targeting specificity. Combinatorial approaches offer several advantages over conventional methods since they allow for the incorporation of multiple components with varied physical-chemical properties into a polymer that will subsequently form NPs by selfassembly or chemical conjugation processes.

In the last few years, several reviews have covered the advances in NP formulations for the delivery of biomolecules including non-coding RNAs and mRNAs. [15] [16] [17] [18] This review focus in the role of high-throughput synthesis of drug delivery systems may facilitate the translation of non-coding RNA and mRNA into the clinic. Therefore, this review discusses the current challenges and future directions of high-throughput screening for the development of more efficient drug delivery systems, particularly in the context of non-coding RNAs and mRNAs. Initially, we cover historic facts about HTS, how/when the HTS was applied to the area of drug delivery, preparation of NP libraries, and the impact of HTS approaches in medicine. Finally, we discuss how this research area might advance in the near future and the expected impact.

HTS emerged as a valuable technique for new lead discovery, both for the academia and industry. HTS allows researchers to test, in a time-and cost-efficient manner, large libraries of compounds using miniaturized in vitro assays designed to interrogate a given biological function. HTS foundations can be traced to the pharmaceutical industry in the early 1990s and were driven by the: (1) urgency to outpace the drug developing pipeline of competitors, (2) advances in cell biology and genomics (Human genome project) that endowed companies with novel tools and know-how (e.g., synthesis of recombinant proteins and gene editing tools), and (3) investment in laboratory automation. 19, 20 Prior to the debut of HTS, screening of new drugs was a slow and costly process limited to around 100 000 candidates ($20 000/ year) with candidate molecules synthesized and kept dry on vials and weighted and diluted manually. 19 Nowadays, the success rate of HTS in drug discovery has been reported to be approximately 50%. 21 The libraries of most big pharma companies engaged in HTS are between 0.5 and 4 Â 10 6 compounds. 22 In some cases, the hits need to be further optimized to yield a drug of interest. From 58 drugs (for which the starting lead was known) approved between 1991 and 2008, 19 drugs have been identified by HTS. 21 HTS assays were designed to be safe, sensitive, robust, and cost-effective. Typically, an HTS assay required the preparation and optimization of a library of compounds, followed by a primary screening where the readout was suitable to interrogate a large number of compounds in a fast and cost-efficient manner. Upon identification of "hits," confirmatory screenings were designed and implemented, and the identified "leads" were tested in more complex in vitro and in vivo models prior to clinical trials.

The introduction of HTS to the field of nanomaterials for controlled drug release has been pioneered by Langer and co-workers in the beginning of the 21st century 23, 24 (Table I) . Initial focus was given to polymeric libraries, because the starting materials were easily available and cheap, and the synthesis process was done without intermediary purification steps. The studies reported the synthesis and unbiased screening of a large library of biodegradable cationic polymers and oligomers for their capacity to work as gene delivery systems ( Fig. 1) . 25 These initial steps were then followed by HTS studies with libraries of linear-dendritic hybrid polymers (that assemble with DNA to form NPs), 26 libraries with photodegradable photocrosslinked materials, 27 and lipid-like nanoformulations for DNA, siRNA, and mRNA delivery, both in in vitro and in vivo models. [28] [29] [30] [31] In many of these studies, the HTS comprised of the high-throughput synthesis of large NP libraries followed by their testing in cell models and finally validation in an in vivo model. More recently, and because of the poor correlation between in vitro and in vivo potency of the formulations, researchers have moved directly to in vivo models after NP synthesis. 32

Combinatorial approaches for the synthesis of polymers or lipids offer several advantages over conventional methods, since they allow the integration of multiple components with varied properties into a nanosystem via self-assembly or chemical conjugation. Because of the number of studies, we will mostly focus on polymeric NPs, but, in general, the approaches can be extrapolated for the synthesis of lipid NPs. High-throughput synthesis and screening is crucial in polymer design, because polymer composition directly affects properties such as drug loading, stability in circulation, and targeting to different cell types. The first approach relies on the self-assembly of macromolecular building blocks with specific functionalities to yield a large variety of NP systems. These self-assembled nanosystems with diverse functionalities can then be rapidly screened in a high-throughput fashion for selection of the best candidates, or hits, which are further evaluated for safety and efficacy. Parallel synthesis of combinatorial polymeric libraries can be achieved manually or robotically both in solid support and in solution. In solid-phase assisted synthesis, sequence-defined polymers can be prepared with high precision using several synthetic strategies such as phosphoramidite coupling, thiolactone/Michael, triazine, thiol-ene, and CuAAC click chemistry. 33, 34 For example, artificial oligoamino acids, such as succinoyl-tetraethylene pentaamine and succinoyl-pentaethylene hexamine, in combination with natural aamino acids, have been used to generate sequence-defined cationic polymers. 35 Using this strategy and a step-by-step optimization of topology, 36 inclusion of small chemical delivery motifs such as tyrosine trimers, 37 histidines, 38 fatty acids, 39 disulfide-forming groups, 40 and targeting ligands, 41, 42 it was possible to synthesize a large library of more than 1000 oligomers. Despite the advantages of using solid-phase synthesis of polymers, several disadvantages can be associated with this methodology such as (i) limited scalability, (ii) excessive use of reagents, (iii) additional deprotection steps after coupling reaction, and (iv) need for very efficient coupling reactions. Alternatively, liquid synthesis uses well-established reaction strategies and easily scalable methods. Large chemically diverse libraries have been synthesized using simple synthetic routes including, but not limited to, Michael addition, 28,43-55 epoxide chemistry, 56-61 reductive amination, 62 thiol-ene/thiol-yne chemistry, 63-66 thiolactone chemistry, 67 and direct alkylation of amines 68 (Fig. 2 ). For example, Michael addition polymerizations have been extensively investigated in the synthesis of linear or hyperbranched poly(b-amino ester)s (PBAE) and poly(amido amine)s (PAA). 23 The PBAEs and PAAs are synthesized via a one-pot Michael addition of amines to acrylates without production of any side products. A large library comprising 2350 polymers has been synthesized for gene delivery applications. 69 A unique advantage of this method was that the synthesis of the polymers and their testing could be performed in "one-pot" without the need for purification or solvent removal, thus allowing the screening of large libraries involving a reduced number of steps. Michael addition was also used in the synthesis of several libraries of lipidoids mainly used for gene delivery. 28, [70] [71] [72] [73] [74] Nevertheless, despite its simplicity, this synthetic strategy requires high temperature or long reaction time (up to several days).

To overcome this limitation, other synthetic reactions were explored. Typically, thiolactone and thiol/ene chemistries require less time for the synthesis of polymers. For example, a library of 840 polyesters has been synthesized based on a polycondensation reaction of trimethylolpropane allyl ether and diacyl chlorides during 24 h, followed by the functionalization with amino and alkyl amines by thiol-ene addition. 64 Other libraries have been synthesized based on a one-pot three-component reaction via thiolactone opening by an amine, followed by a disulfide exchange reaction. 75 The reaction to obtain the 25 lipidoids was completed after 2 h and was performed at room temperature. It should be noted that in certain cases, long synthetic procedures or complicated purification steps were major drawbacks in the synthesis of nanomaterials libraries. 72 The elimination of steps in polymer purification, such as the use of rotary evaporator or precipitation in a solvent to obtain the purified polymer, removed a time-consuming step in the high-throughput process. 76 A multitude of design parameters and combinations thereof can contribute to the precise fine-tuning of a highly efficient material for a specific application. It is worth mentioning that the biocompatibility and biodegradability of any synthetic polymer used to synthesize NPs for intravenous injection are highly strict. For a material, the biocompatibility refers to its ability to perform its function with an appropriate host response. This means that the material itself, as well as all the degradation products released during its lifetime, must not elicit any toxic effect in the host. 77 In turn, the biodegradability of the material has to be ensured to avoid the accumulation of NPs in the body. 

scitation.org/journal/apb HTS and combinatorial design of NP libraries can be a valuable approach to allow rapid and simultaneous screening of multiple formulations with specific release and cell/tissue targeting properties. For example, a combinatorial library of lipid NPs was developed for the in vivo delivery of siRNAs to leukocytes. 90 These amino lipid molecules were constructed using a microfluidic system that assembled cholesterol, ionizable lipid, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEGylated lipids. Modifications to the linker backbone, lipid chain, and/ or the headgroups resulted NPs with different sizes that ultimately led to differences in cell viability, transfection efficiency, internalization, biodistribution in organs, and ultimately differences in gene silencing efficiency in leukocytes. NPs with a hydroxylamine linker backbone had improved gene silencing in lymphocytes, while NPs with a hydrazine linker had no effect. Thus, the importance of using diverse libraries of NPs is crucial to identify formulations capable of eliciting the desired biological response while overcoming deleterious side-effects. The selection of the starting material should be the first step on the development of an HTS assay and should take into consideration downstream applications such as the route of administration of the nanoformulation or the potential cytotoxic effects from the nanomaterials.

Development and screening of nanomaterial libraries with different compositions and properties will contribute to accelerate the identification of the most suitable delivery system for a given biological application. Yet, developing suitable screening platforms with high accuracy, coupled with a rapid method of analysis, is challenging. In many cases, the selection of lead compounds relies on an extensive characterization of the NP library using cellular models for the in vitro screening followed by the selection of a limited number of formulations for in vivo testing. [91] [92] [93] [94] [95] [96] Yet this paradigm is changing since recent studies have adopted to test the NP formulations after their synthesis immediately in animal models. 14, 97 A well-designed and implemented cell-based HTS assay can provide several outputs such as NPs toxicity, uptake, and efficacy data. In the HTS performed in the last 20 years, the following cellular readouts have been reported: (i) gene knockdown, 91, 92 (ii) gene knockout, 93, 94 (iii) cell viability, 98, 99 and (iv) expression of a cellular reporter. 95, 96 In most of these HTS studies, the effect of the nanoformulations was evaluated by optical methods including absorbance, 100 fluorescence, 101 and luminescence, 28,56 using plate readers or high content microscopes. 102, 103 Drug development usually follows an inverted pyramid approach to organize and generate knowledge (Fig. 3) . Usually, following the primary screening, multiple confirmatory screenings are performed to validate the original hits. While in the first screening, a rough approach is conducted to identify selective and efficient compounds, during secondary screenings, a more detailed analysis can be run to further validate compounds using different types of assays. Secondary assays may rely on the use of (i) purified NPs, (ii) NPs tested at different doses, (iii) in different types of cells, (iv) synthesis of NPs in large scale, among others. Secondary screens can confirm the hits of the primary screen and provide insights regarding the mechanism of action. As an example, a secondary screen was important to show the effect of polymer molecular weight (MW) in the bioactivity of the nanoformulations. 104 Two polymers with identical structures but with different MWs had distinct cell activity. Secondary screens have also been performed to demonstrate the intracellular delivery efficiency and cellular tropism of hit formulations. For example, the uptake of dual-ligand liposomes was initially demonstrated in a 2D cell culture model, followed by 3D tumor spheroid models and finally by in vivo studies. 105 

Following an extensive characterization of the NP library using in vitro models, one should be able to select a small group of NPs for in vivo evaluation. To overcome the lack of information pertaining, for 

scitation.org/journal/apb example, the toxicity of the NPs at the organism-level, the use of small well-characterized organisms for high-throughput toxicological assessment emerged as an important strategy. Among these, Caenorhabditis elegans 106 and Danio rerio (zebrafish) models 107, 108 have been used in a high-throughput manner to assess NP's toxicity. Notwithstanding, complex mammalian organisms, such as rodents and non-human primates, are important at the preclinical stage to obtain pharmacological information data due to their similarity with humans. 62, 109 Recently, advances have been made to predict, using high-throughput in vitro assays, the in vivo behavior of NPs. For example, a chemically diverse library of 30 lipid NPs was constructed in order to perform a fast screening of NPs biodistribution in tissues and cells. 110 Each of these NPs carried particular nucleic acid cargos-termed "barcodes"-that were administered as a single pool to mice. Using deep sequencing as a high-throughput methodology, the authors were able to identify the exact location of these NPs in the mice lungs, heart, or liver with high sensitivity and specificity. This target-specific approach overcomes the off-target delivery of NPs that often occur in vitro, hasten up the preclinical studies and contributes to the study of the relation of chemical structure and biological function. Later, the authors also demonstrated that this barcode system could be used to track more than 150 NPs, at the same time, in vivo. 111 However, one of the limitations of this methodology lies on the fact that only NPs that are stable prior to parenteral administration will be retained in vivo, thus missing potentially interesting nanoformulations. Importantly, this barcode strategy was used to demonstrate that the in vitro delivery of NPs in static cell cultures did not predict the in vivo delivery, one of the major drawbacks of the use of nanomaterials. 111

HTS has an important role in the progress of the drug delivery area, because it: (i) allows the identification of formulations without the need of an hypothesis and (ii) allows structure-function relationship analyses, providing new insights that can be used to assist design and optimization of new libraries. [112] [113] [114] The use of HTS allowed researchers to understand the impact of factors such as the polymer's MW, 115 the pKa, 43,116 the hydrophilicity/hydrophobicity of the hydrocarbon chain, 43, 81, 117 the type of amine groups, 43,118 type of end-functional groups, 81,104 the degradation kinetics, 91,92,119 and the number and saturation level of the hydrocarbon chains. 102 For example, from a library of 2000 NPs, the most effective NP formulation for siRNA delivery was formed by a low MW polymer. 115 In addition, HTS studies in 32 116 or 1400 43 lipid formulations showed that NPs pKa has a strong correlation with in vitro and in vivo data than NPs size or NPs loading. Indeed, HTS studies showed that lipid nanoformulations with a pKa in the range of 5.5-7 had higher in vitro an in vivo activity than the ones with low pKa. 43, 116 Moreover, other HTS studies indicate that parameters, such as NP disassembly and NP internalization, do not correlate with formulation activity. 91, 92, 119 HTS was important for early steps in the delivery programs of non-coding RNAs. 28 The development of Patisiran, a lipid NP containing siRNA for the treatment of hereditary transthyretin amyloidosis, 120 required more than 10 years of development and the screen of more than 300 ionizable lipids. 14 The approved NP formulation contains the ionizable cationic lipid Dlin-MC3-DMA, which has a head group containing tertiary amines that are uncharged at neutral pH but protonated under acidic conditions, helper lipids, and PEG-containing lipids. 121 Many aspects of the NP formulation have been carefully designed such as the size, encapsulation efficiency, scalable manufacturing processes, and formulation stability. Yet the delivery of biomolecules to other organs than liver remains a challenge. Recent progresses with lipid NPs seem to indicate that the incorporation of specific charged lipids in lipid NPs may control the tropism of the NPs to specific organs (liver, lung and spleen). 97 Yet, more progresses are needed to develop NP formulations able to reach with high efficiency organs such as the heart or the brain.

The information collected from HTS studies was critical for the rapid development of COVID-19 mRNA vaccines. 7, 8 The mRNA of some COVID-19 vaccines is released by lipid NPs (Fig. 4) . These NPs have four components: ionizable lipids to allow the interaction with mRNA, pegylated lipids to increase circulation time of the formulation by preventing opsonization of plasma proteins and the uptake of macrophages, and phospholipids and cholesterol that contribute for the NP structure. These NP formulations may be further improved to protect the mRNA overtime, potentially without requiring so low temperatures of storage, and potentially to increase their intracellular efficacy.

In this review, we have covered recent progresses in the synthesis of combinatorial nanomaterials for the delivery of biomolecules. The use of simple, convenient, and efficient chemical synthesis strategies has facilitated the parallel and combinatorial synthesis of small and large libraries of nanomaterials with diversified chemical structures. Indeed, chemistry has a crucial role in accelerating material discovery, and this will lead to new types of nanomaterials with different physical-chemical properties capable of increasing targeting and responsiveness.

We anticipate several progresses in the area of HTS applied to drug delivery by the: (i) use of in vitro models of increasing complexity (e.g., spheroids, micro-tissues, and organoids), (ii) use of techniques with single cell resolution, (iii) combinatorial screening by automated microfluidics, (iv) use of better structure-activity correlation models, and (v) more effective development of NP formulations able to target organs other than liver.

Regarding the first point, in many diseases, the inhibition of a single target is not enough to have a therapeutic proposition. In addition, cells do not behave in the same way when are cultured in monoculture or in a living tissue. Therefore, a more faithful in vitro representation of the in vivo biology will impact HTS in the development of more efficient drug delivery systems. It is important to mimic, in as much as possible, the in vivo cellular environment by controlling, for example, the flow, type of extracellular matrix, intercellular communication (particularly with vascular and immune cells), cellular heterogeneity, or even the off-target effect of the NPs. The in vivo complexity can be achieved by using co-cultures systems, 3D culture platforms, patient-derived adult-or iPSC-derived cells, and even microfluidic "organ-on-a-chip" models. 98, 122, 123 In the last 30 years, some studies have used three-dimensional (3D) cell cultures in order to recapitulate the complexity of the in vivo organization. These 3D cell cultures can adopt different formats such as multicellular structures derived from more than one type of cell (e.g., micro-tissues and co-culture systems), cell aggregates from a single cell type (also termed spheroids), 124 and organoids that are derived from cells differentiated from a progenitor cell population with capacity to form organ-like structures. 125 Many of HTS studies documented so far with nanomaterial libraries have not explored the use of 3D cell cultures or intact organs ex vivo. 126 Aside from recapitulating the in vivo environment or pathophysiological conditions, these are important for understanding the NPs trafficking, targeting, and biological effects at the subcellular level. The use of whole organs requires the use of appropriate tissue-clearing methods coupled with complex imaging systems and algorithms to observe the complex tissue architecture. 127 This is an area that will grow in the coming years, as it is now being explored for drug discovery and precision medicine. 128 However, there are major limitations of 3D cell culture that still need to be overcome, namely, of: (i) scalability to multi-well microplates, (ii) automation, (iii) need of appropriate imaging systems for the visualization of 3D structures in an high throughput fashion (e.g., automated high-throughput lightsheet fluorescence microscopy that was only launched in 2018), 129 (iv) compatibility of systems (from NP library synthesis and liquid handling equipment to automated screening and analysis), and (v) reproducibility.

Regarding the second point, the readouts of most HTS studies are limited to major alterations in cell phenotype such as morphology, proliferation, migration, and cell death. It is expectable that in the near future, the readouts in HTS will increase in complexity by the use of single-cell transcriptome sequencing (scRNA-seq) 130 as well as single cell proteomics. 131 Recent advances in these techniques enable costeffective HTS at single cell resolution. For example, the cost of scRNA-seq library preparation is now less than $0.01 per cell allowing the profiling of millions of cells per experiment. 132 This has been demonstrated recently in the screen of 188 compounds in three cancer cell lines. The authors have profiled approximately 650 000 single cell transcriptomics across 5000 independent samples in one experiment. The results highlighted the heterogeneity in cellular response to a perturbation induced by a chemical compound and the possibility to distinguish the effect of a unique compound in different cell populations in a tissue or a 3D in vitro model.

Regarding the third point, the HTS studies performed so far are unable to provide combinatorial and dynamic drug treatments. Microfluidics offers a simple to use, rapid, low-cost (with low reagent consumption), and high-throughput approach for the development of NPs' libraries with controlled structures that increase the reproducibility of assays. 117, 133 Even though microfluidics had a great evolution in the synthesis of NP libraries, its use on combinatorial screening is far from sufficient. Recent advances in microfluidic systems enable the performance of multiple assays in parallel in highly reproducible environment with the utilization of minimal volumes of cell culture media as well as formulations. 134 These automated systems may open other avenues of research in the area of HTS for drug delivery systems, because they allow the alteration of the concentration of the formulation as well as the timing and derivation of their effect in 2D or 3D cell cultures.

Regarding the fourth point, recent advances in machine learning and the capacity to model big data may allow us to infer better structure: function relationships. 135, 136 For example, the phase behavior of lipid NPs has been successfully predicted using machine learning. By varying ratios of saturated and unsaturated fatty acids or the chain length of the lipids, it elucidated the contributions of various factors and may serve as a bridge to deduce the delivery efficiency of the formulations in in vitro or in vivo. [137] [138] [139] In another example, the integration of high-throughput experimentation with machine learning led to the identification of 100 drug NPs with high loading capacity. 140 In addition, the use of machine learning tools can be envisioned as a strategy to identify new principles for more efficient release 141 and targeting 135 to specific cells.

Regarding the fifth point, the translation of mRNA and gene editing therapies require the development of delivery systems with tropism to specific organs. Current NP formulations have poor targeting efficiency to organs beyond the liver. A recent study has reported the development of lipid NPs to target organs such as the liver, lung, or spleen following NP intravenous administration. 97 In this case, the incorporation of a charged lipid component in the NP formulation affected their organ targeting capacity. Yet, further progresses are needed to develop NP formulations able to target efficiently organs such as the heart or the brain. Therefore, in the coming years, it is expectable that HTS of NP formulations with variable effect of morphology, charge, pKa, hydrophilicity/hydrophobicity, among other factors, will be developed to address this issue.

In summary, high-throughput combinatorial synthesis and screening have proven to be a powerful strategy to obtain efficient nanoparticles for drug delivery with clinical relevance, particularly non-coding RNAs and mRNAs. It is expectable that in coming years, the combination of HTS of NP formulations with organoids and the use of scRNA-seq and machine learning tools to determine the biological impact of the released drugs will have a significant impact in the design of more efficient drug delivery systems.

Strategies in the design of nanoparticles for therapeutic applications

Light-triggerable formulations for the intracellular controlled release of biomolecules

Nanoparticles in the clinic

First-in-man study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia

Alnylam launches era of RNAi drugs

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): A multicentre, phase 2-3, randomised, controlled trial

pdf for more information about the Pfizer/BioNTech COVID-19 mRNA Vaccine (Comirnaty

for more information about the Moderna COVID-19 mRNA Vaccine (nucleoside-modified

Nanoparticles in the clinic: An update

Combination therapy in combating cancer

Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: Pathways for translational development and commercialization

Challenges and strategies in anti-cancer nanomedicine development: An industry perspective

Patisiran's path to appoval

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo

Advances in biomaterials for drug delivery

Emerging frontiers in drug delivery

Novel advances in targeted drug delivery

Polymeric nanoparticles: Promising platform for drug delivery

History, evolution, and trends in compound management for high throughput screening

Origin and evolution of high throughput screening

Impact of high-throughput screening in biomedical research

Shaping a screening file for maximal lead discovery efficiency and effectiveness: Elimination of molecular redundancy

Accelerated discovery of synthetic transfection vectors: Parallel synthesis and screening of a degradable polymer library

Parallel synthesis and biophysical characterization of a degradable polymer library for gene delivery

Degradable poly(b-amino esters): Synthesis, characterization, and self-assembly with plasmid DNA

A family of hierarchically self-assembling linear-dendritic hybrid polymers for highly efficient targeted gene delivery

A combinatorial library of photocrosslinkable and degradable materials

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

Combinatorial library of lipidoids for in vitro DNA delivery

Development of lipidoid-siRNA formulations for systemic delivery to the liver

Lipid-like nanoparticles for small interfering RNA delivery to endothelial cells

The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

Recent developments in solid-phase strategies towards synthetic, sequence-defined macromolecules

Digging into the sequential space of thiolactone precision polymers: A combinatorial strategy to identify functional domains

Optimized solid-phase-assisted synthesis of oleic acid containing siRNA nanocarriers

Comb-like oligoaminoethane carriers: Change in topology improves pDNA delivery

Stabilizing effect of tyrosine trimers on pDNA and siRNA polyplexes

Fine-tuning of proton sponges by precise diaminoethanes and histidines in pDNA polyplexes

Structure-activity relationships of siRNA carriers based on sequence-defined oligo (ethane amino) amides

Bioreducible polycations as shuttles for therapeutic nucleic acid and protein transfection

Nanosized multifunctional polyplexes for receptormediated siRNA delivery

Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand

Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity

Combinatorial library of cyclic benzylidene acetal-containing pH-responsive lipidoid nanoparticles for intracellular mRNA delivery

Protein and mRNA delivery enabled by cholesteryl-based biodegradable lipidoid nanoparticles

Combinatorial library of chalcogen-containing lipidoids for intracellular delivery of genome-editing proteins

Synthesis of poly(-beta-amino ester)s optimized for highly effective gene delivery

A polymer library approach to suicide gene therapy for cancer

Beta-amino ester polymers facilitate in vivo DNA transfection and adjuvant plasmid DNA immunization

Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumors

Structure/property studies of polymeric gene delivery using a library of poly(beta-amino esters)

Biodegradable polymeric vectors for gene delivery to human endothelial cells

A combinatorial polymer library approach yields insight into nonviral gene delivery

Poly(beta-amino ester)-DNA complexes: Time-resolved fluorescence and cellular transfection studies

Small-molecule end-groups of linear polymer determine cell-type gene-delivery efficacy

Lipid-like materials for low-dose, in vivo gene silencing

Small RNA combination therapy for lung cancer

Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression

Endothelial siRNA delivery in nonhuman primates using ionizable low-molecular weight polymeric nanoparticles

Therapeutic siRNA silencing in inflammatory monocytes in mice

Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells

Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates

Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model

Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells

A biomimetic lipid library for gene delivery through thiol-yne click chemistry

Single-tailed lipidoids enhance the transfection activity of their double-tailed counterparts

Combinatorial synthesis of a lipidoid library by thiolactone chemistry: in vitro screening and in vivo validation for siRNA delivery

Combinatorial synthesis and high-throughput screening of alkyl amines for nonviral gene delivery

Semi-automated synthesis and screening of a large library of degradable cationic polymers for gene delivery

Branched-tail lipid nanoparticles potently deliver mRNA in vivo due to enhanced ionization at endosomal pH

Enhanced intracellular siRNA delivery using bioreducible lipid-like nanoparticles

Imidazole-based synthetic lipidoids for in vivo mRNA delivery into primary T lymphocytes

Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery

Synergistic silencing: Combinations of lipid-like materials for efficacious siRNA delivery

Marrying chemistry with biology by combining on-chip solution-based combinatorial synthesis and cellular screening

Automated high-throughput synthesis of protein-loaded polyanhydride nanoparticle libraries

Biological Performance of Materials: Fundamentals of Biocompatibility

Synthesis of high-entropy alloy nanoparticles on supports by the fast moving bed pyrolysis

The manufacturing techniques of drug-loaded polymeric nanoparticles from preformed polymers

Polyelemental nanoparticle libraries

Combinatorial modification of degradable polymers enables transfection of human cells comparable to adenovirus

High throughput surface characterisation of a combinatorial material library

Polymer surface functionalities that control human embryoid body cell adhesion revealed by high throughput surface characterization of combinatorial material microarrays

Combinatorial discovery of polymers resistant to bacterial attachment

Ionizable amino-polyesters synthesized via ring opening polymerization of tertiary amino-alcohols for tissue selective mRNA delivery

Combinatorial library of lightcleavable lipidoid nanoparticles for intracellular drug delivery

Degradable terpolymers with alkyl side chains demonstrate enhanced gene delivery potency and nanoparticle stability

Polymer-lipid nanoparticles for systemic delivery of mRNA to the lungs

Poly(beta-amino ester)-co-poly(caprolactone) terpolymers as nonviral vectors for mRNA delivery in vitro and in vivo

A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes

A light-triggerable formulation to control the stability of proangiogenic transcription factor hypoxia inducible factor-1alpha (HIF-1alpha)

A high-throughput screening platform to identify nanocarriers for efficient delivery of RNA-based therapies

Intracellular delivery and biodistribution study of CRISPR/Cas9 ribonucleoprotein loaded bioreducible lipidoid nanoparticles

Poly(beta-amino ester) nanoparticles enable nonviral delivery of CRISPR-Cas9 plasmids for gene knockout and gene deletion

A novel high-throughput cell-based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug delivery

A robust and high-throughput Cre reporting and characterization system for the whole mouse brain

Selective organ targeting (SORT) nanoparticles for tissuespecific mRNA delivery and CRISPR-Cas gene editing

A combinatorial library of biodegradable polyesters enables non-viral gene delivery to post-mitotic human stem cell-derived polarized RPE monolayers

Solid-phase combinatorial synthesis using microarrays of microcompartments with light-induced on-chip cell screening

A combined high-throughput and high-content platform for unified on-chip synthesis, characterization and biological screening

Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach

One-pot parallel synthesis of lipid library via thiolactone ring opening and screening for gene delivery

A high-throughput Galectin-9 imaging assay for quantifying nanoparticle uptake, endosomal escape and functional RNA delivery

Rapid optimization of gene delivery by parallel endmodification of poly(beta-amino ester)s

Microfluidic self-assembly of a combinatorial library of singleand dual-ligand liposomes for in vitro and in vivo tumor targeting

Multi-endpoint, high-throughput study of nanomaterial toxicity in Caenorhabditis elegans

High content screening in zebrafish speeds up hazard ranking of transition metal oxide nanoparticles

A library of AuNPs modified by RAFT polymers of different charge and chain length: High throughput synthesis and synchrotron XFM imaging using a zebrafish larvae model

High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing

Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics

A direct comparison of in vitro and in vivo nucleic acid delivery mediated by hundreds of nanoparticles reveals a weak correlation

Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells

Biomaterial microarrays: Rapid, microscale screening of polymer-cell interaction

Combinatorial material mechanics: High-throughput polymer synthesis and nanomechanical screening

In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight

Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery

Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation

Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery

A light-triggerable nanoparticle library for the controlled release of non-coding RNAs

Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis

Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads

Cellular uptake of gold nanoparticles and their movement in 3D multicellular tumor spheroids: Effect of molecular weight and grafting density of poly(2-hydroxyl ethyl acrylate)

Characterization of four functional biocompatible pressure-sensitive adhesives for rapid prototyping of cell-based lab-on-a-chip and organ-on-a-chip systems

A high-throughput automated confocal microscopy platform for quantitative phenotyping of nanoparticle uptake and transport in spheroids

Organogenesis in a dish: Modeling development and disease using organoid technologies

Three-dimensional optical mapping of nanoparticle distribution in intact tissues

Assessing micrometastases as a target for nanoparticles using 3D microscopy and machine learning

A fully automated high-throughput workflow for 3D-based chemical screening in human midbrain organoids

Automated high-throughput light-sheet fluorescence microscopy of larval zebrafish

Massively multiplex chemical transcriptomics at singlecell resolution

Defining the carrier proteome limit for single-cell proteomics

The single-cell transcriptional landscape of mammalian organogenesis

Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy

Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids

Machine learning predicts the functional composition of the protein corona and the cellular recognition of nanoparticles

Exploration of the nanomedicine-design space with high-throughput screening and machine learning

High-throughput screening of saturated fatty acid influence on nanostructure of lyotropic liquid crystalline lipid nanoparticles

Manipulating the ordered nanostructure of self-assembled monoolein and phytantriol nanoparticles with unsaturated fatty acids

Using machine learning to predict the self-assembled nanostructures of monoolein and phytantriol as a function of temperature and fatty acid additives for effective lipid-based delivery systems

Computationally guided high-throughput design of selfassembling drug nanoparticles

Predicting coated-nanoparticle drug release systems with perturbation-theory machine learning (PTML) models